alpha-(n6-adenyl)styrene oxide has been researched along with 3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine in 1 studies
Studies (alpha-(n6-adenyl)styrene oxide) | Trials (alpha-(n6-adenyl)styrene oxide) | Recent Studies (post-2010) (alpha-(n6-adenyl)styrene oxide) | Studies (3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine) | Trials (3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine) | Recent Studies (post-2010) (3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine) |
---|---|---|---|---|---|
8 | 0 | 2 | 7 | 0 | 2 |
Protein | Taxonomy | alpha-(n6-adenyl)styrene oxide (IC50) | 3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine (IC50) |
---|---|---|---|
Vif | Human immunodeficiency virus 1 | 31.51 | |
Tat | Human immunodeficiency virus 1 | 4.29 | |
DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | 31.51 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Butkiewicz, M; Lowe, EW; Meiler, J; Mendenhall, JL; Mueller, R; Teixeira, PL; Weaver, CD | 1 |
1 other study(ies) available for alpha-(n6-adenyl)styrene oxide and 3-(3,4-dihydro-2H-quinolin-1-ylmethyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine
Article | Year |
---|---|
Benchmarking ligand-based virtual High-Throughput Screening with the PubChem database.
Topics: Algorithms; Animals; Area Under Curve; Computer Simulation; Databases, Chemical; Decision Trees; Drug Discovery; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Ligands; Models, Chemical; Neural Networks, Computer; Quality Improvement; Quantitative Structure-Activity Relationship; ROC Curve; Support Vector Machine | 2013 |